SCHEMBL5656161

SCHEMBL5656161

O=C1CN=C(c2ccccc2)c2cccc(Cl)c2N1CC(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.64
NR1I2 O75469 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
OPRM1 P35372 1/20 0.64
NPSR1 Q6W5P4 2/20 0.53
GAA P10253 2/20 0.47
HTT P42858 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 6/20 0.45
GABRA1 P14867 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA5 P31644 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249926 0.82 NR1I2 (0.74) OPRK1NR1I2ADORA3OPRM1NPSR1
Halazepam SCHEMBL78995 0.78 OPRK1 (1.00) OPRK1NR1I2ADORA3OPRM1NPSR1
Halazepam SCHEMBL29375979 0.78 OPRK1 (1.00) OPRK1NR1I2ADORA3OPRM1NPSR1
SCHEMBL5656546 0.77 GABRP (0.46) OPRK1NR1I2ADORA3OPRM1TP53
Halazepam SCHEMBL28086644 0.74 OPRK1 (0.85) OPRK1NR1I2ADORA3OPRM1NPSR1
SCHEMBL13352364 0.74 OPRK1 (0.76) OPRK1NR1I2ADORA3OPRM1NPSR1
SCHEMBL11770631 0.71 OPRK1 (0.62) OPRK1NR1I2ADORA3OPRM1NPSR1
SCHEMBL7858451 0.71 HDAC3 (0.63) OPRK1NR1I2ADORA3OPRM1NPSR1
SCHEMBL9088703 0.69 TP53 (0.61) OPRK1NR1I2ADORA3OPRM1NPSR1
Halazepam SCHEMBL28086105 0.69 OPRK1 (0.77) OPRK1NR1I2ADORA3OPRM1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641781-B1 Benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME (US) 2013-03-06 EP disclosed
US-7196079-B2 Benzodiazepine CGRP receptor antagonists MERCK & CO, INC. (US) 2007-03-27 US disclosed
US-20060148790-A1 Benzodiazepine cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-07-06 US disclosed
EP-1641781-A2 BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2006-04-05 EP disclosed
WO-2005000807-A2 BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148790-A1 Benzodiazepine cgrp receptor antagonists BDKRB1, CCKBR, BDKRB2 OPRK1 13/4885NR1I2 339/4885ADORA3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.